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Abstract
It has been estimated that there are more than 60 million Hepatitis C virus (HCV) carriers in the World Health Organisation’s
Western Pacific region (WHO-WPR), where liver cancer is among the top three causes of cancer death. WHO and the US
Centres for Disease Control and Prevention report the prevalence of HCV in the South Pacific islands (countries within the
WHO-WPR) to be high (5–10% and .2% respectively). However, since HCV is not tested for in many of these countries, there
is sparse data available to support this assertion. We screened ,2000 apparently healthy individuals from Papua New
Guinea, Fiji and Kiribati and found a sero-prevalence of 2.0%, 0.1% and 0%, respectively. All sero-positive samples tested
negative for HCV RNA. Curious as to why all the sero-positive individuals were negative for HCV-RNA, we also screened
them for the HCV protective IL28B SNP markers rs12979860 and rs8099917. All antibody-positive participants bar one had
HCV protective haplotypes. Our results suggest that HCV is present in these Pacific island countries, albeit at a prevalence
lower than previous estimates. As none of our participants had undergone antiviral treatment, and therefore must have
cleared infection naturally, we hypothesise that genotypes 1 and/or 4 are circulating in South Pacific Island people and that
these peoples are genetically predisposed to be more likely to spontaneous resolve HCV infection than to become chronic
carriers.
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Introduction
Isolated in 1989, the hepatitis C virus (HCV) has since been
found to be a globally diverse, positive sense, RNA virus,
belonging to the Flaviviridae family, and is classified into at least
7 genotypes and numerous subtypes [1–4]. Each genotype, and
subtype, displays different patterns of endemic and epidemic
epidemiology. For example, subtype strains such as 1a, 1b, 2a, 2b,
3a, and 4a, are linked with 20th century outbreaks caused by the
use of unscreened blood products, illicit drug injecting, or non-
sterile medical injections [5–10]. In contrast, other local endemic
strains appear to have been present in particular populations for
many centuries, such as genotypes 1 and 2 in West Africa and
genotype 6 in South East Asia. Genotype 6, for example, exhibits a
very high degree of genetic diversity, and evolutionary molecular
clock analyses suggest that the subtypes of this genotype diverged
at least 1000 years before present [6].
HCV exposure in 50–80% of cases (depending on host and virus
factors) [11–14] leads to a chronic infection that can in turn result in
chronic liver disease, liver cirrhosis and liver cancer, each resulting
in considerable morbidity and mortality. The high prevalence of
HCV infection makes it a health problem of international
importance. Studies over the last 23 years have identified that
clinical outcomes depend on both host and viral factors. For
example, individuals infected with genotype 1 are less likely to clear
viral infection upon treatment [15]. Recent genome-wide associa-
tion studies findings have identified haplotypes of single nucleotide
polymorphic markers (SNPs) strongly associated with spontaneous
and treatment-induced clearance in genotypes 1 and 4 (i.e., the C in
haplotype rs12979680, and the T in haplotype rs8099917) [16–18].
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The primary risk factor for HCV infection is exposure to
infected blood or blood products, for example, via unscreened
blood transfusions or cutaneous injury with HCV contaminated
needles, piercing instruments, tattoo pens, or surgical and dental
instruments. Throughout the 21st century the causes of local
epidemics have included unsafe medical practices, illicit injecting
drug users (IDUs), and unsafe vaccination practises. Whilst rare,
HCV can also be transmitted via sexual exposure. HCV has also
been detected in saliva, breast milk, urine, and faeces, as well as
semen and cervico-vaginal secretions [10].
Any effort to prevent transmission and control HCV requires
accurate epidemiological data. Serological screening assays have
played a major role in understanding HCV epidemiology and
have reduced the risk of HCV transmission and the global disease
burden considerably. Unfortunately there is much debate with
regards to their most efficacious usage and interpretation [19–24].
The many tests vary in cost, sensitivity, and efficiency resulting in a
plethora of recommendations on appropriate use and interpreta-
tion. The implementation of efficacious screening programs in the
developing South Pacific Island Countries (SPICs) is primarily
hindered by cost, but is also problematic because these assays
commonly produce biological false-positive reactions, particularly
in populations of low HCV prevalence and in tropical environ-
ments where the frequent level of exposure to other pathogens
(such as malaria and dengue virus) can cause cross reactivity
[11,25–28]. Nonetheless, there have been a few HCV prevalence
surveys in SPICs; the earlier screening surveys (from serum
samples collected as early as 1984, but predominantly from 1990–
91) presented anti-HCV sero-prevalence rates up to 8% [29–34].
More recent studies, circa 2006, have estimated lower infection
rates of 2–4% [35]. Despite HCV being endemic world-wide and
despite there being strong indicators of HCV presence in SPICs,
the true epidemiology of HCV infection in the developing nations
of the 22 SPICs is not known, as the resources for high-quality
studies are not readily available and national screening procedures
are not in place.
Here we estimate the frequency of HCV sero-reactivity and
RNA carriage in three SPICs Papua New Guinea (PNG), Fiji and
Kiribati, amongst otherwise healthy adults. These three low-to-
middle income nations (as classified by the World Bank) carry a
high burden of Hepatitis B Virus (HBV) [36,37]. The use of
marijuana and alcohol is widespread in these Pacific Island
societies and is closely associated with unprotected sexual activity
and acts of sexual violence, however, injecting drug use is not
recognised to be prevalent in the region. The incidence of injecting
drug abuse is considered to be extremely rare (pers. comm. Dr
Kelly, PNG Institute of Medical Research); it has only been
recorded as the mode of transmission in one case of HIV
transmission. Interestingly tattooing is also not considered to be an
important risk factor [39], it remains to be seen if penile injecting,
which is wide spread in the region, is similarly not associated. Fiji
introduced HCV serological screening for transfused blood in
2006 but neither PNG nor Kiribati screen, therefore in these
countries exposure via unscreened blood transfusion remains the
primary risk factor for HCV transmission.
Results
Table 1 provides a summary of the results of the serological
assays by age, sex and country, Table 2 provides a summary of the
results by country alone, and Table 3 gives the results by town
within PNG. Table S1 presents the serological results including the
signal-to-cut-off (S/CO) ratios, the results of the nucleic acid
testing (NATs) and the IL28B results. Fourteen PNG, one Fijian
(an adult female) and zero I-Kiribati samples tested reactive for
both the Ortho HCV3 assay and the anti-HCV Monolisa assay.
In PNG there were considerable provincial differences in HCV
sero-reactivity. Samples were collected at sites representing 5 of
the 19 provincial regions in PNG: Central Province (Port
Moresby), Western Province (Daru), Madang Province (Madang),
Eastern Highlands Province (Goroka), and Western Highlands
Province (Mt Hagen). All samples collected from Daru, Goroka,
and Mt Hagen were negative for HCV; 2.2% and 9.6% of the
samples collected in Port Moresby and Madang respectively,
tested positive. We found no significant difference in prevalence
between men and women (2-tailed Fisher’s Exact Test) nor
between those ,50 and those .50 years old (2-tailed Fisher’s
Exact Test). S/CO ratios (see Methods) from both assays were
calculated and compared and we found inconsistent results
between the assays. Five samples tested with the Ortho 3 assay
consistently had S/CO ratios greater than $3.8 (samples P_047,
P_130, P_242, PW018 and PW064) but only two tested with the
Monolisa assay had a ratio $5 (samples P_109 and P_130). This
lack of consistency reaffirms the difficulty in scoring HCV-positive
samples in a resource-poor setting where the more specific
recombinant immunoblot assay (RIBA) tests or HCV-NAT testing
may not be available.
Duplicate NATs for HCV RNA were conducted on all samples
that gave a reactive serologic screening response. No viral RNA
was detectable in any sample. As part of the original HBV study
we were required to return to the collection sites and provide
follow-up support and feedback from the study. On our last visit in
2008, three of the participants that screened reactive for HCV
returned for follow up; at this later time they were re-bled and
retested and none were HCV RNA positive.
The IL28B haplotype results are listed in Table S1. There was
considerable homogeneity in the populations sampled. All but one
of the fifteen sero-positive samples were homozygous for the major
allele C in haplotype rs12979860 and all were homozygous for the
major allele T in rs8099917. The remaining sample, P_242, was
heterozygous for the rs12979860 SNP. The CC/TT genotype is
strongly associated with spontaneous and treatment-induced
clearance in genotypes 1 and 4. [16,17,38]. A further eighty-eight
individuals from the same three countries were typed for the
rs8099917 SNP as part of another study and the results were also
homogeneous (see Table S2).
Discussion
Our results demonstrate a national HCV sero-prevalence of
2.2% in PNG, 0.1% in Fiji, and 0% in Kiribati, considerably less
than previously reported but in line with the few published reports
of the sero-prevalence in the SPICs [33,35,39]. However, we
observed considerable variability in HCV sero-prevalence among
the sample sites. Five sites were screened in PNG but HCV
reactivity was found in only two locations (Port Moresby and
Madang). These two towns are in lowland coastal areas with
moderately well-supported hospitals and infrastructure, both have
a notable influx of foreign workers and tourists, and both are towns
that were established early in PNG colonial history. Any one of
these factors may have introduced the virus to these particular
provinces. HCV is unlikely to have become established by IDUs.
A handful of IDUs from PNG have been reported in behavioural
survey studies, but there is no known IDU cohort or culture, nor
reliable estimates of IDU prevalence in PNG [40]). It is unlikely
that the 9.6% sero-prevalence we found in Madang reflects the
general population exposure, as closer inspection revealed that the
sample population was enriched for high-risk exposure partici-
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pants such as health-care workers or people that handled blood as
part of their profession (e.g. nurses or phlebotomists). Indeed,
individuals PW013, PW017, PW023, PW062, PW064, and
PGM016 were all health-care workers of some kind. The
possibility that HCV exposure might be so prevalent amongst
health-care workers highlights the need for better awareness and
control.
Interestingly, in concordance with all previously published
studies from SPICs, no HCV RNA could be confirmed in any of
the samples [29,30,32,35]. For our initial samples collected in
2005, inappropriate long-term storage could be a reason for the
lack of detection of HCV-RNA. However, for the three individuals
retested in 2008 this is not the case as each sample was tested for
HCV-RNA within an hour of the blood samples being drawn.
Neither HCV screening nor treatment are available in PNG and
none of the HCV-positive individuals indicated in their initial
interview that they were aware of having had HCV. Therefore the
infected individuals will most likely have spontaneously cleared the
infection. Spontaneous clearance estimates for HCV range from
15–50% depending on the population being sampled [11,14,41].
Clearance has been attributed to various factors, including host
innate and adaptive immunity as well as being associated with
particular genetic markers such as the Il28 SNPs [14,17,18]. We
screened all our HCV antibody-positive samples for the
rs12979860 and rs8099917 SNPs; all but one individual was
homozygous for the ‘‘protective’’ C and T haplotypes respectively.
Thus a high rate of HCV clearance in these individuals may have
been enhanced by the presence of these favourable IL28B alleles -
it is plausible that the individuals who were HCV sero-positive but
PCR negative may have had only a transient infection that
spontaneously resolved. Previous work by Thomas et al. 2009 [17]
who screened for the rs12979860 SNP, and by Shebl et al. 2011
[42] who screened for rs12979860 and rs8099917 markers, and a
separate parallel study of our own (where eighty-eight individuals
from the same three countries where screened for the rs8099917
SNP; see Table S1) have demonstrated a 70–100% prevalence of
the major ‘protective’ rs12979860 and rs8099917 haplotypes in
indigenous SPIC populations. However, these haplotypes are only
associated with spontaneous viral clearance of genotypes 1 and 4
and no information is available regarding the circulating genotypes
in these populations. If the HCV strain circulating in PNG is an
ancestral endemic strain then it is more likely to be genotype 6 (the
endemic strain circulating in South East Asia) or perhaps a close
relation. If HCV was recently introduced it is more likely to be one
of the epidemic strains such as subtypes 1a, 1b, 2a, 2b or 3a [6].
The prevalence and preponderance of HCV makes it a global
health problem and accurate epidemiological data must underpin
any effort to prevent transmission and control the virus.
Unfortunately the epidemiology of HCV infection in SPICs is
not well characterised [29–35]. National blood transfusion services
exist in the region, to ensure a safe and secure supply as well as use
of blood and blood products but only a few SPICs screen for
HCV. There is no information regarding circulating genotypes. In
SPICs, IDUs are extremely rare, and to date scarification and
tattooing has shown no association with HCV [36]. Consequently,
blood transfusions very likely present the greatest risk of infection.
Clearly the primary risk factor for HCV infection (i.e., exposure to
infected blood or blood products) remains neglected. We were
fortunate in having a sample bank of sera collected from mother-
child pairs and healthy adults in PNG, Kiribati and Fiji that were
collected for the purpose of viral hepatitis research. From this
bank, 2224 serum samples were made available for screening and
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Finally, there is much debate over the correct interpretation of
serological test results, particularly in a resource-poor setting
where RIBA testing or HCV-NAT testing may not be available. In
our study five samples scored ‘‘truly positive’’ in the Ortho-3 assay
and two in the BioRad assay, but only one sample scored ‘‘truly
positive’’ in both assays. This reaffirms the difficulty in scoring
HCV positive samples. In our work we chose to follow
recommendations from the WHO and Owusu-Ofori et al 2005
[23] and scored samples as either past, or presently positive if
positive in two assays. We find this to be more practical than using
the S/CO ratios.
This study has revealed that the HCV sero-prevalence rate in
SPICs is variable but generally lower than previously estimated.
We were unable to detect HCV RNA and define genotypes in this
extensive survey. The ability to assess accurately the burden of
HCV disease is clearly important in defining public health
priorities, as well as, indicating the history and the likely future
impact of this infection. The high rate of false-positives using a
single screening test suggests that caution must be applied in
interpreting such assays, particularly in low-prevalence settings
where there is a high burden of other chronic infections. Applying
such a cautious multi-layered approach will be of value in
determining the impact of HCV endemic and epidemic strains in
diverse global populations.
Finally, we note that, despite the relatively low frequency of
HCV, the rate of liver cancer in this region is still very high. The




A collection of serum samples from PNG, Fiji and Kiribati was
obtained during a study of the molecular epidemiology and
evolution of HBV in the region. 1500 mother and child sample
pairs and 1000 adult serum samples were collected between 2003
and 2005. Ethical permission for the blood sample collection and
subsequent HCV research was obtained from each country
through the appropriate national committees and/or Ministries
of Health. In PNG and Fiji, permission was obtained via the PNG
National Medical Research Advisory Committee and the Fiji
National Research Ethics Review Committee, respectively. In
Kiribati there was no established ethical review committee at the
time of the project, therefore extensive consultation with the
Ministry of Health and local medical professionals was conducted
before the project began. Signed informed consent was obtained
from each participant. Although the primary purpose of the study
focused on the hepatitis B virus in the Pacific, informed participant
permission was also granted to screen for HCV. In all three
countries convenience group sampling was applied. In PNG blood
samples were collected from participants present at outpatient
clinics at regional hospitals in Port Moresby, Goroka, Mt Hagen,
Madang, and Daru. These participants were either escorting
family members or friends to the clinic or came specifically to be
tested for HBV. Approximately 314 from Port Moresby were
volunteer parents attending their children at the childrens’ ward at
Port Moresby General Hospital. All blood samples from Fiji were
collected in Suva from the Colonial War Memorial Hospital either
from the outpatients’ clinic or from parents attending their
children in the childrens’ ward as above. In Kiribati samples were
collected from parents at village preschools and from vaccination
clinics on North Tarawa and North Tabiteuea. The samples
included people from each of the 19 provinces of PNG, the various
ethnic groups living in Fiji (Indigenous-Fijian, Indo-Fijian, Rotu-
man, and other Pacific Islanders) and each of the 12 Gilbert atolls
of Kiribati. Blood was collected by venupuncture and serum was
separated and stored at 220uC. Our sampling was targeted at
adults in the community or mother-child pairs, but no specific
Table 2. Serological HCV results by country.
Sample size Number seropositive
Prevalence (maximum
likelihood estimate) Prevalence (95% lower CI)Prevalence (95% upper CI)
Kiribati 657 0 0% 0% 0.5%
Fiji 904 1 0.1% ,0.01% 0.7%
PNG 644 14 2.2% 1.3% 3.6%
Abbreviations: %, percentage; CI, Confidence Interval.
doi:10.1371/journal.pone.0066749.t002
Table 3. Serological HCV results by town in Papua New Guinea.
Papua New Guinea







Port Moresby 322 7 2.2% 1.00% 4.5%
Daru 91 0 0% 0% 3.5%
Madang 73 7 9.6% 4.5% 18.7%
Goroka 59 0 0% 0% 5.3%
Mt Hagen 99 0 0% 0% 3.2%
Total 644 14 2.2% 1.3% 3.6%
Abbreviations: %, percentage; CI, Confidence Interval.
doi:10.1371/journal.pone.0066749.t003
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inclusion/exclusion criteria were applied. Anyone who wished
to be tested was tested. On occasions when a patient presented
with hepatitis-like illness (e.g. jaundice) they were tactfully
approached (if deemed healthy enough to provide informed
consent by their attending physician). However there were only
three such patients; none were HCV positive and 2 were HBV
positive. Questionnaires were completed for each blood donor
providing information on (amongst other things) age, sex,
symptoms of liver dysfunction, blood transfusions, occupation
and tattoos. From this set, 2224 serum samples were selected
and screened for HCV.
Serology
There are a plethora of guidelines for the use of HCV enzyme
immunoassays (EIA). We chose to incorporate guidelines from
WHO, Atlanta CDC, and Owusu-Ofori et al 2005 [23] as briefly
outlined below. WHO advise that it is important to use assays with
a minimum overlap of both false-positive and false-negative
reactions. They recommend using both the Ortho 3.0 Enhanced
SAVe (Ortho 3) (Ortho Clinical Diagnostics) and Monolisa anti-
HCV Plus version 2 (Monolisa) (Bio-Rad; formerly Sanofi
Diagnostics Pasteur) as initial screening assays. They further
recommend that these screening assays are then confirmed by
either the Chiron recombinant immunoblot assay (RIBA) or via
nucleic acid testing (NAT) [22]. In addition, the use of signal-to-
cut-off (S/CO) ratios are recommended, as these have been found
to be a better predictor of sample status.
Alter et al. 2003 [20] reported that in a population where
carriage is approximately 2% approximately 80% of the Ortho 3
reactive samples with a S/CO ratio of ,3.8 were in fact negative,
whilst approximately 97% of those reactive with a S/CO ratio
greater than 3.8 were truly positive. They conclude that any
samples with a S/CO ratio of less than 3.8 should be retested and
anything greater than 3.8 can be considered positive. Similar
evaluations of the Monolisa assay by Perry et. al., 2001 [24]
indicated that only 5% of positive samples have a S/CO ratio less
than 5. This is supported by Centres for Disease Control and
Prevention Atlanta USA (CDC) and the Microbiological Diag-
nostics Assessment Service UK (MiDAS) [20,43]. Their results
suggest using S/CO ratio values to predict HCV-RNA positives,
those that have been exposed but have cleared, and false-positive
infections.
Owusu-Ofori et. al., 2005 [23] suggest an alternative, simpler
protocol for resource-poor country screening. They recommend
that samples reactive to two or more EIA should be considered
positive for past or present infection.
Ortho 3.0 Enhanced SAVe (Ortho Clinical Diagnostics), and
Monolisa anti-HCV Plus version 2 system (Bio-Rad formerly
Sanofi Diagnostics Pasteur), EIA screening assays were carried out
at the Division of Transfusion Medicine, Department of Haema-
tology, Addenbrookes Hospital Cambridge in a two-step process.
To identify putative positives, the sera were initially screened for
HCV using the Ortho 3.0 Enhanced SAVe ELISA test system, (a
qualitative enzyme-linked immunosorbent assay for the detection
of antibody to HCV), as per the standard kit protocols. Any
sample that tested reactive, or equivocally reactive, was then tested
twice more. In step two, all 36 Ortho 3.0 reactive samples, as well
as 150 randomly selected non-reactive (negative) samples, were
then rescreened in triplicate with the Monolisa Anti-HCV Plus
version 2 BioRad test system. S/CO ratios were calculated for all
reactive samples. In our study, any sample that was positive for
both the Ortho 3.0 and Monolisa tests was considered to be HCV
antibody positive.
Nucleic Acid Testing (NAT)
Next, viral RNA was extracted from all sera that tested reactive
in either screening tests using Qiagen miniprep. Standard
extraction protocols were used, with the modification that 500 ml
of sera was first centrifuged at maximum rpm for 1 hour to
concentrate the viral particles. From this, 360 ml of sera was
pipetted off and RNA was then extracted from the remaining
140 ml. A 300 nt fragment of the NS5B and a 200 bp fragment of
the 59UTR regions were RT-PCR amplified as per the protocols
outlined in Murphy et. al. 2007 [4] Table 4 provides the primer
sequences for both regions. As the genotypes circulating in the
region are unknown, primer combinations that would amplify all
genotypes were used. RNA and DNA amplifications were
conducted using both Superscript II for two-step amplifications,
and Superscript III Platinum Taq for one-step amplifications
(Invitrogen Life Sciences), followed by nested reactions with Roche
Hifi Expand (Roche Diagnostics) using standard protocols.
Controls were run in parallel at each step.
IL28B typing
The confirmed HCV antibody positive participants (that is, sera
samples positive in both serological assays) were haplotyped for
both rs8099917 and rs12979860.
The rs8099917 haplotype was determined using TaqMan allelic
discrimination with custom Assays-on-Demand products from
Applied Biosystems (C__11710096_10) and confirmed by PCR
reactions with Roche Hifi Expand polymerase (Roche Diagnos-
tics). The rs12979860 haplotype was determined using nested
PCR reactions with Roche Hifi Expand polymerase, standard
protocols and Sanger sequencing. The primers used are listed in
Table 4.
Table 4. Primers.
Primer Primer sequences Genotype
59UTR Ex F1 CCCTGTGAGGAACT(AT)CTGTCTTCACGC All
59UTR In F3 TCTAGCCATGGCGTTAGT(AG)(CT)GAG All
Core Ex R2 GGTGCACGGTCTACGAGACCT All
Core In R4 CACTCGCAAGCACCCTATCAGGCAGT All
NS5B Ex F TGGGGATCCCGTATGATACCCGCTGCTTTGA 1–5 & ‘7’
NS5B Ex R CGGAATTCCTGGTCATAGCCTCCGTGAA 1–5 & ‘7’
NS5B ExF G6 CCHATGGGGTTYTCCTAYGACAC 6
NS5B ExR G6 GGNGCYGAGTAYCTGGTCATGGC 6
NS5B In F GACACCCGCTGCTTTGACTC All
NS5B In R GAGTCTTCACGGAGGCTATGACNAGGTA All
860 Ex F GCGCTTATCGCATACGGCTAG rs12979860
860 Ex R CCCAGCAGGCGCCTCTCCTA rs12979860
860 In F CCTGGACGTGGATGGGTACTG rs12979860
860 In R GCAGGCGCCTCTCCTATGTCAG rs12979860
917 Ex F CATACAACATGGAGAGTTAAAGTAAGTC rs8099917
917 Ex R GCTGGCCCCAGGAGCTTGCACTAG rs8099917
917 in R CCTGTGCTGGGCCACCACAATTCA rs8099917
Primers used in RT-PCR, and PCR reactions of the 59UTR and NS5B region of HCV
and the nested amplifications of the IL28B SNPs. Genotype 7 is in quotations as
it is yet to be confirmed as a new genotype. TaqMan SNP typing for rs8099917
was conducted using custom Assays-on-Demand products from Applied
Biosystems (C__11710096_10) and verified with the listed primers, using
standard PCR and sequencing techniques.
doi:10.1371/journal.pone.0066749.t004
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